New and improved scientific method to forecast the demand for key anti-malarial treatments
The study, published by Cell Press in the January 15th issue of the journal Neuron, provides intriguing insight into how human behavior can be guided by the perceived behavior of other individuals. Many studies have demonstrated the profound effect of group opinion on individual judgments, and there is no doubt that we look to the
Full Post: New research reveals brain activity that underlies our tendency to “follow the crowd”
Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.
While this may sound simple, ensuring a sufficient supply of effective drugs to each country that needs them remains a challenge until the demand for those drugs is accurately predicted and understood. A new and improved scientific method to forecast the demand for a key anti-malarial treatment may be the key for how science and economics can and should intersect to maintain low-cost, high-quality drugs to combat infectious diseases. According to Justin Cohen, M.P.H., Ph.D., such a forecast is crucial in order to supply enough medications to meet demand — especially since demand has the potential to rise very rapidly as old drugs lose effectiveness and governments switch to new drugs.
Dr. Cohen and his team from the Clinton Foundation started looking for patterns in how funding for drugs is disbursed around the world and used those patterns to forecast how future funding will look. The team used a similar approach to forecasting the demand for HIV/AIDS treatments in Africa. It worked so well that the team decided to set its sights on the treatment of malaria, which now affects 300-500 million people per year - 1 million of whom die from the disease. The cost to Africa’s economy alone is estimated to be $12 billion per year.
The quantitative method centers on the acquisition of a chief anti-malarial ingredient, artemisinin, which comes from plants and is used in malaria treatments. One of the challenges with artemisinin-based combination therapy (ACT) is it can take up to two years for the plants to grow, extract the artemisinin and then for pharmaceutical companies to develop the drugs. If demand isn’t accurately predicted, it can lead to a shortage of drugs, driving up the cost for countries to buy them. Conversely, an oversupply can lead to drugs “going bad” as they sit on the shelf past their expiration dates. This is why forecasting demand is vital.
Dr. Cohen will explore the following points at the ASTMH Annual Meeting, December 7-11 in New Orleans:
- The anti-malarial world, from farmers up to drug producers, was disorganized and inefficient because there was little understanding of the demand for treatments. Past forecasts, including by the World Health Organization, vastly overstated expected demand;
- The first-ever robust and scenario-based global forecast of ACT demand, which shows that demand will at least double over the coming four years and could grow by as much as 327 percent to over 400 million treatment packs if a global ACT subsidy is launched;
- The forecast helped to support the signing of agreements with suppliers to reduce the volatility in artemisinin supply, reduce drug prices, and help ensure access to high-quality, low-cost drugs.
Three emerging technologies have the potential to significantly improve supplies of drugs to combat malaria, according to a report published today. With renewed efforts to eradicate malaria - a disease which kills up to one million people every year, most of them young children - the global demand for antimalarials is set to increase dramatically
Full Post: New technologies improve supplies of drugs to combat malaria
The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS) has reached the milestone of the 75th anti-retroviral generic drug approved or tentatively approved as part of President Bush’s Emergency Plan for AIDS Relief (PEPFAR). Marketed by Macleods Pharmaceuticals, Ltd, of Kachigam, Daman, in the Republic of India, the
Full Post: FDA grants tentative approval for 75th generic anti-retroviral drug
In the quest to develop the next generation of anti-infective medicine, Griffith University and Pfizer, the world’s largest research-based pharmaceutical company, announced a leading partnership today. Griffith University’s Eskitis Institute for Cell and Molecular Therapies investigates novel drug- and cell-based therapies for human diseases in the areas of cancer, infection and immunity, neglected diseases,
Full Post: Griffith University and Pfizer in new partnership to unlock nature’s cure for infections
This year, the U.S. Food and Drug Administration is expected to approve the first malaria drug to contain artemisinin, a wormwood derivative from China that has proven effective for malaria in Africa and Asia. Although there are only about 1,500 reported cases of malaria treated in this country each year, this approval would also make
Full Post: First artemisinin based malaria drug may meet resistance, expert says
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly. In a study funded by the Wellcome Trust and Fight for Sight and published in the Journal of Infectious Diseases, researchers in Malawi have shown for
Full Post: The retina reveals deadly secrets of malaria